Compare · ACRS vs ATHE
ACRS vs ATHE
Side-by-side comparison of Aclaris Therapeutics Inc. (ACRS) and Alterity Therapeutics Limited (ATHE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACRS and ATHE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ACRS is the larger of the two at $608.9M, about 10.1x ATHE ($60.2M).
- Over the past year, ACRS is up 194.3% and ATHE is down 18.2% - ACRS leads by 212.5 points.
- ACRS has been more active in the news (8 items in the past 4 weeks vs 6 for ATHE).
- ACRS has more recent analyst coverage (18 ratings vs 3 for ATHE).
- Company
- Aclaris Therapeutics Inc.
- Alterity Therapeutics Limited
- Price
- $4.37+0.00%
- $3.91-2.49%
- Market cap
- $608.9M
- $60.2M
- 1M return
- -10.27%
- -15.73%
- 1Y return
- +194.28%
- -18.20%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 8
- 6
- Recent ratings
- 18
- 3
Aclaris Therapeutics Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Alterity Therapeutics Limited
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.
Latest ACRS
- Director Molineaux Christopher P. converted options into 11,580 shares, increasing direct ownership by 20% to 69,536 units (SEC Form 4)
- Director Milano Vincent converted options into 11,580 shares, increasing direct ownership by 67% to 28,896 units (SEC Form 4)
- Director Mehra Anand converted options into 11,580 shares, increasing direct ownership by 2% to 726,403 units (SEC Form 4)
- Director Humphries William D. converted options into 11,580 shares, increasing direct ownership by 35% to 45,105 units (SEC Form 4)
- Director Schiff Andrew N converted options into 11,580 shares, increasing direct ownership by 83% to 25,540 units (SEC Form 4)
- Director Gowen Maxine converted options into 11,580 shares, increasing direct ownership by 53% to 33,334 units (SEC Form 4)
- Aclaris Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
- SEC Form 10-Q filed by Aclaris Therapeutics Inc.
Latest ATHE
- SEC Form 6-K filed by Alterity Therapeutics Limited
- SEC Form 6-K filed by Alterity Therapeutics Limited
- SEC Form 6-K filed by Alterity Therapeutics Limited
- SEC Form 6-K filed by Alterity Therapeutics Limited
- Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
- SEC Form 6-K filed by Alterity Therapeutics Limited
- SEC Form 6-K filed by Alterity Therapeutics Limited
- Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
- SEC Form 6-K filed by Alterity Therapeutics Limited
- Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026